We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer.
- Authors
Sheikh, Nadeem A; Petrylak, Daniel; Kantoff, Philip W; Dela Rosa, Corazon; Stewart, Frances P; Kuan, Ling-Yu; Whitmore, James B; Trager, James B; Poehlein, Christian H; Frohlich, Mark W; Urdal, David L
- Abstract
Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for treatment of advanced prostate cancer, is manufactured by activating peripheral blood mononuclear cells, including antigen presenting cells (APCs), with a fusion protein containing prostatic acid phosphatase. Analysis of data from three phase 3 trials was performed to immunologically characterize this therapy during the course of the three doses, and to relate the immunological responses to overall survival (OS).
- Publication
Cancer immunology, immunotherapy : CII, 2013, Vol 62, Issue 1, p137
- ISSN
1432-0851
- Publication type
Journal Article
- DOI
10.1007/s00262-012-1317-2